Department of Surgery, Section of Otolaryngology/Head and Neck Surgery, University of Chicago, IL, USA.
Head Neck. 2012 Aug;34(8):1162-7. doi: 10.1002/hed.21888. Epub 2011 Nov 3.
Patients with T4 laryngeal cancers, including those with large-volume (cartilage or tongue-base invasion) lesions, are often excluded from organ-preservation trials due to expectations of inferior outcome in terms of survival and function. We hypothesize that such patients indeed have acceptable survival and function when treated with organ-preservation strategies.
Retrospective analysis of prospectively collected data of a cohort of patients with T4 laryngeal cancer was carried out. Follow-up ranged from 0.18 to 15.6 years. All T4 laryngeal cancer patients who were enrolled in the University of Chicago concomitant chemoradiotherapy protocols from 1994 to the present were reviewed. This study was composed of 80 newly diagnosed T4 laryngeal cancer patients. Efficacy of treatment was determined through evaluations of survival and function. Survival was evaluated via Kaplan-Meier methods. Swallowing function was evaluated by an oropharyngeal motility (OPM) study and swallowing scores were assigned. Higher scores reflected increasing swallowing dysfunction.
Fifty-five of 80 patients (69%) had documented large-volume tumor. Two- and 5-year overall survivals were 60.0% and 48.7%, respectively. Disease-specific 2- and 5-year survivals for the group were 80.1% and 71.3%, and 79.4 and 74.3%, respectively, for the 55 patients with large volume status. Progression-free survival rates were 52.6% and 47.6%. Forty-four of 65 patients (68%) with OPM data had a Swallowing Performance Status Scale (SPSS) score of ≤5, indicating various degrees of swallowing abnormalities not requiring a gastrostomy tube. This is a functional-preservation rate of 67.7%.
Chemoradiation for patients with T4 laryngeal cancer appears to be an effective and reasonable option, particularly in light of the satisfactory survival and function-preservation rates.
T4 喉癌患者,包括那些有大体积(软骨或舌底侵犯)病变的患者,由于对生存和功能方面的预后较差的预期,通常被排除在器官保留试验之外。我们假设,对于接受器官保留策略治疗的此类患者,他们的生存和功能确实可以接受。
对一组 T4 喉癌患者前瞻性收集数据的回顾性分析。随访时间从 0.18 年到 15.6 年不等。从 1994 年至今,所有入组芝加哥大学同期放化疗方案的 T4 喉癌患者均被纳入本研究。本研究共纳入 80 例新诊断的 T4 喉癌患者。通过评估生存和功能来确定治疗效果。生存通过 Kaplan-Meier 方法进行评估。吞咽功能通过口咽运动(OPM)研究进行评估,并分配吞咽评分。评分越高,反映吞咽功能障碍越严重。
80 例患者中有 55 例(69%)有记录的大体积肿瘤。总的 2 年和 5 年生存率分别为 60.0%和 48.7%。该组疾病特异性的 2 年和 5 年生存率分别为 80.1%和 71.3%,55 例大体积肿瘤患者的生存率分别为 79.4%和 74.3%。无进展生存率分别为 52.6%和 47.6%。有 OPM 数据的 65 例患者中有 44 例(68%)的吞咽表现状态量表(SPSS)评分≤5,表明存在不同程度的吞咽异常,不需要胃造口管。这是 67.7%的功能保留率。
对于 T4 喉癌患者,放化疗似乎是一种有效且合理的选择,尤其是考虑到满意的生存率和功能保留率。